<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990766</url>
  </required_header>
  <id_info>
    <org_study_id>201901107</org_study_id>
    <nct_id>NCT03990766</nct_id>
  </id_info>
  <brief_title>Smell Changes &amp; Efficacy of Nasal Theophylline</brief_title>
  <acronym>SCENT</acronym>
  <official_title>SCENT Trial: Nasal Theophylline Irrigation for Treatment of Post-Viral Olfactory Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of nasal theophylline irrigation in treating&#xD;
      smell loss related to a viral respiratory infection. Half the participants will undergo nasal&#xD;
      theophylline irrigation treatment while the other half will undergo placebo nasal irrigation&#xD;
      with saline alone. All participants will have their sense of smell tested before and after 6&#xD;
      weeks of treatment. All participants will also be regularly asked about any potential side&#xD;
      effects related to treatment. In addition, the first 10 participants will have their blood&#xD;
      drawn to measure their theophylline level after 1 week of starting treatment to ensure it is&#xD;
      not abnormally elevated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two randomized arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Global Rating of Smell Change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-reported change in smell after intervention on a 7-point Likert scale. Response options with corresponding point values: 7) Much better, 6) Somewhat better, 5) Slightly better, 4) Neither better nor worse, 3) Slightly worse, 2) Somewhat worse, and 1) Much worse. The maximum score is 7, and higher values indicate better outcomes. A score of 4 is considered neutral.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>University of Pennsylvania Smell Identification Test (UPSIT) Change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Within- and between-subject changes in UPSIT scores. This test is a validated 40-question forced-choice odor identification test where microencapsulated odorants on a strip are released by scratching. The maximum score is 40, and higher values indicate better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS) Change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Within- and between-subject changes in QOD-NS scores, which is a validated 17-item questionnaire about quality of life and impairments related to olfactory dysfunction. The maximum score is 51, and higher values indicate worse quality of life or higher degree of impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Olfactory Dysfunction Outcomes Ratings (ODOR) Change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Within- and between-subject changes in ODOR. This test is a new disease-specific 28-item questionnaire that assesses for physical, functional, and emotional limitations in patients with olfactory dysfunction of any etiology. The maximum score is 112, and higher values indicate higher degree of limitations and worse outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Olfactory Disorder</condition>
  <condition>Anosmia</condition>
  <condition>Viral Infection</condition>
  <condition>Theophylline Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Smell Disorder</condition>
  <arm_group>
    <arm_group_label>Theophylline saline irrigation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride &amp; Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo saline irrigation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride &amp; Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>Theophylline delivered via high-volume, low-pressure nasal saline irrigation</description>
    <arm_group_label>Theophylline saline irrigation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Nasal</intervention_name>
    <description>Lactose delivered via high-volume, low-pressure nasal saline irrigation</description>
    <arm_group_label>Placebo saline irrigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjective or clinically diagnosed olfactory dysfunction of 6 months to 36 months&#xD;
             duration after a presumed viral upper respiratory infection&#xD;
&#xD;
          -  Ability to read, write, and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dependence on theophylline for comorbid conditions such as asthma and chronic&#xD;
             obstructive pulmonary disease&#xD;
&#xD;
          -  History of an allergic reaction to theophylline or other methylxanthines&#xD;
&#xD;
          -  Prior sinonasal or anterior skull base surgery&#xD;
&#xD;
          -  Nasal polyposis&#xD;
&#xD;
          -  History of neurodegenerative disease (ie. Alzheimer's dementia, Parkinson's disease,&#xD;
             Lewy body dementia, frontotemporal dementia)&#xD;
&#xD;
          -  Pregnant or breastfeeding mothers&#xD;
&#xD;
          -  Current use of medications with significant (â‰¥40%) interactions with theophylline,&#xD;
             which include cimetidine, ciprofloxacin, disulfiram, enoxacin, fluvoxamine,&#xD;
             interferon-alpha, lithium, mexiletine, phenytoin, propafenone, propranolol, tacrine,&#xD;
             thiabendazole, ticlopidine, and troleandomycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Olfactory dysfunction</keyword>
  <keyword>Anosmia</keyword>
  <keyword>Hyposmia</keyword>
  <keyword>Post-viral</keyword>
  <keyword>Theophylline</keyword>
  <keyword>Adverse effects</keyword>
  <keyword>Smell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Anosmia</mesh_term>
    <mesh_term>Olfaction Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

